Yahoo Finance • 11 days ago
Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicitiesLasting, durable responses observed out to 18 months in adult particip... Full story
Yahoo Finance • 29 days ago
RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small mol... Full story
Yahoo Finance • 2 months ago
– Phase 1/2 trial expected to initiate in 2H 2025 in patients with BEST1 inherited retinal disease RESEARCH TRIANGLE PARK, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company d... Full story
Yahoo Finance • 2 months ago
Investing.com - Opus Genetics (NASDAQ: IRD) reported second quarter EPS of $-0.120, $0.07 better than the analyst estimate of $-0.190. Revenue for the quarter came in at $2.88M versus the consensus estimate of $4.04M. Opus Genetics’s stoc... Full story
Yahoo Finance • 2 months ago
- Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 - - FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation fo... Full story
Yahoo Finance • 3 months ago
RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small mole... Full story
Yahoo Finance • 4 months ago
Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuitySafety profile consistent with previous clinical trials and no treatment-related serious adverse events reported in the s... Full story
Yahoo Finance • 4 months ago
Opus Genetics, Inc. (NASDAQ:IRD) announced Wednesday that Chief Financial Officer Nirav Jhaveri has departed the company following a termination without cause. According to a press release statement based on a filing with the Securities an... Full story
Yahoo Finance • 4 months ago
Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placebo Phase 3 study showed patient-reported functional benefit in treating significant, chronic night driving impairm... Full story
Yahoo Finance • 6 months ago
NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView today published a Q&A feature with Dr. George Magrath, Chief Executive Officer of Opus Genetics, Inc. (“Opus Genetics” or the “Company”) (Nasdaq: IRD), a clinical-stage gene t... Full story
Yahoo Finance • 6 months ago
Board Timed Highly Dilutive Financing to Close on the Record Date for the Annual Meeting, Tilting the Vote and Forcing the Withdrawal of the Restore Value Slate Second Major Transaction in Six Months Undertaken Without Stockholder Input w... Full story
Yahoo Finance • 6 months ago
First pediatric patient shows encouraging early safety profile and meaningful improvement in visual function at one month A second pediatric patient was recently dosed, and the pediatric cohort is expected to complete enrollment in Q2 202... Full story
Yahoo Finance • 6 months ago
Provides update on the Company’s transformation and promising portfolio of innovative gene therapy treatments for inherited retinal diseases Strong cash position with $21.5 million financing to supplement $30.3 million year-end balance N... Full story
Yahoo Finance • 7 months ago
Believes that Current Board’s Strategic, Management and Capital Allocation Failures have Resulted in Stockholder Value Destruction Highlights Serious Concerns with the Opus Merger and the Company’s Underperformance Preliminary Proxy Mate... Full story
Yahoo Finance • 7 months ago
RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and th... Full story
Yahoo Finance • 7 months ago
RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (“Opus” or the “Company”) (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited reti... Full story
Yahoo Finance • 7 months ago
Durham, NC., March 05, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other ophthalmologi... Full story
Yahoo Finance • 8 months ago
First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025 New 12-month data on the first three adult OPGx-LCA5 patients to be presented at a major medical conference... Full story
Yahoo Finance • 8 months ago
Current Board’s Strategic, Management, and Capital Allocation Failures Have Driven an 80% Stock Decline Over Last 22 Months New Leadership is Urgently Needed to Restore Accountability in the Boardroom Restore Value Slate Brings Deep Indu... Full story